Andreessen Horowitz is a venture capital firm specializing in investing in seed, start-ups, early, mid-stage, growth, and late-stage. It prefers to invest in the social media business and technology sector with a focus on software, back-end infrastructure, the infrastructure of the Internet, cloud computing, enterprise software and services, consumer, business Internet, mobile-Internet, consumer Internet, cloud computing, data storage, social network browsers data-storage, consumer electronics, networking functions, software related biology, biotech, and medicine companies at the intersection of computer science and life sciences with a focus on digital therapeutics, cloud technology in biology, and computational medicine.

Andreessen Horowitz

Felicis Ventures is a venture capital firm based in Menlo Park, California. The firm invests in seed through Series C stage companies across multiple sectors and industries reinventing core markets, as well as those creating frontier technologies. Felicis currently manages over $2B in capital across 8 funds. The firm is an early backer of more than 40 companies valued at $1B+. More than 90 of its portfolio companies have been acquired or gone public since the firm was founded by Aydin Senkut in 2006.

Felicis

Ulu Ventures is a leading seed-stage venture fund in Silicon Valley investing in diverse entrepreneurial teams as well as Enterprise IT, EdTech, FinTech, Healthcare, and Sustainability startups.  Ulu is the first Latina-led venture fund in Silicon Valley and is one of the largest in the country with over $200M in assets under management. As well, the firm has designed its investment process to reduce risk and produce better, more consistent returns. Ulu’s process structures intuition and applies it intelligently to investments, avoiding cognitive biases common in VC; systematically identifies key drivers of risk and uncertainty, streamlining due diligence; and calculates a probability-weighted multiple(PWM) on invested capital, ensuring consistent decision-making.

Ulu Ventures

Rock Springs Capital is an investment company situated in Baltimore, Maryland. The company specializes in offering advisory services, primarily focused on managing security portfolios and providing portfolio management solutions to businesses and institutional clients. Through its advisory activities, Rock Springs Capital aims to assist clients in optimizing their investment strategies and achieving their financial goals.

Rock Springs Capital

Menlo Ventures provides capital for multi-stage consumer, enterprise, and life sciences technology companies. Since 1976, the firm’s market-driven analysis has led to the identification of opportunities and successful investments in innovative markets. Notable areas of investment include Marketplaces (Uber, Rover.com, Poshmark); Consumer Services (Tumblr, Betterment, Roku, Siri); Dev/Ops (Harness, Edge Delta, Fire hydrant); SaaS (Carta, ScoutRFP, Qualia, Benchling, Everlaw); Fintech (Betterment, Bluevine, Chime); Cybersecurity (Cavium, IronPort, BitSight, Abnormal, StackRox); and Life Sciences Technology (Synthego, Cofactor Genomics, Recursion Pharmaceuticals, 3T Biosciences). Menlo’s portfolio includes more than 70 public companies, and more than 100 mergers and acquisitions, with $5 billion under management. The firm is currently investing in Menlo Ventures XV, a $500 million early-stage fund, as well as its $500 million Inflection Fund, which targets early-growth investments.

Menlo Ventures

T. Rowe Price is an investment management firm dedicated to funding technology startups. The firm serves individuals, financial intermediaries, and institutions and offers a full range of investment strategies across a broad spectrum: debt, equities, and private equities.

T. Rowe Price

Open Field Capital LLC was established in August of 2003 with the exclusive focus of managing portfolios in emerging technology equities.  The founding principals of Open Field Capital have worked together for over 15 years and have a substantial depth and breadth of experience in the financial markets. Throughout that time, the principals have worked in emerging technology markets and have developed both an investment philosophy and methodology tailored to the sector's unique characteristics.

Open Field Capital

JAZZ Venture Partners is the leading venture capital firm focused on technologies that extend the boundaries of human performance. They invest in companies at the intersection of digital technology and neuroscience. They are interested in companies that leverage cutting-edge brain science to inform powerful technology platforms that are impacting the human experience, such as virtual and augmented reality, immersive video gaming, artificial intelligence, and closed-loop human-computer systems. Their portfolio companies are unlocking human potential in important markets: health, mind-body wellness, peak mental and physical performance, accelerated learning and training, sports, and entertainment.  The partners are proven investors, entrepreneurs, neuroscientists, and technologists. They have deep domain experience and unparalleled access to innovative companies, talent, and strategic resources. Their multidisciplinary backgrounds allow us to meaningfully support exceptional entrepreneurs and executives in building category-defining companies.

Jazz Venture Partners

Radical Ventures is an early-stage venture capital firm investing in entrepreneurs applying deep technology to transform massive industries. With a primary focus on artificial intelligence, Radical Ventures partners with entrepreneurs with global ambition to build enduring companies. The firm is based in Toronto, Canada, with offices in London (UK), and Palo Alto (US)

Radical Ventures

Propagator Ventures is an early-stage deep tech VC with strong ties to science

Propagator Ventures

Harpoon is an early-stage venture capital. It was formed in 2018 and is headquartered in San Diego, California.

Harpoon

Fidelity is a privately owned investment management firm that serves a wide range of clients. It offers services including IRAs, rollovers, annuities, discount brokerage, retirement planning, estate planning, wealth management, securities execution and clearance, and life insurance. They serve individual investors, businesses, financial advisors, and institutions. The firm manages equity, fixed-income, and balanced mutual funds and invests in public equity and fixed-income markets. It also conducts in-house research to inform its investment decisions.

Fidelity

BlackRock is an investment management company that provides its services to a diverse range of clients, including institutions, intermediaries, foundations, and individual investors. The firm operates as a global asset manager, overseeing and advising on a wide array of investment portfolios. In addition to its role as an investment manager, BlackRock is also known for its technological innovations and solutions that support various aspects of the financial industry. The company's multifaceted approach encompasses investment management, financial technology, and serving a broad spectrum of clients in the financial ecosystem.

BlackRock

Green D Ventures is a community of accredited Dartmouth alums who pool money into a VC fund to invest in Dartmouth-connected companies. Simply put, they believe they can invest better together than they can alone. They create a diverse portfolio for their investors, co-investing with leading VC funds across industry, stage, and geography. Their goal is to raise a new fund each year that benefits entrepreneurs, the school's ecosystem, and their investors.

Green D Ventures

NVentures is a venture capital firm that invests in early-stage technology companies, focusing on innovations in various sectors. NVentures is the venture capital arm of NVIDIA.

NVentures

Genesis Therapeutic

Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design. Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.

<div>Genesis Therapeutics is an AI-powered biotechnology company engaged in discovering and developing drugs both internally and through partnerships to tackle difficult and previously untreatable medical targets. Genesis uses its proprietary molecular generation engine, PotentialNet, to generate drug molecules and predict molecular properties. The company has also developed Genesis Exploration of Molecular Spaces (GEMS), a molecular AI platform that combines deep learning, molecular simulations, and language models for molecular generation to develop small molecules for therapies.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Genesis Therapeutics

Gilead Sciences, Genesis Therapeutics enter into strategic collaboration to discover, develop novel therapies

Gilead Sciences

To leverage AI for developing innovative small molecule therapies, enhancing drug discovery efficiency, and potentially improving Gilead's earnings per share in 2024.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Genentech

To leverage Genesis Therapeutics' AI capabilities to discover potential drug candidates for various diseases, with Genentech selecting the disease targets and sharing royalties from any successful drugs.

<div>
 
 Genesis Therapeutics is an AI-powered biotechnology company engaged in discovering and developing drugs both internally and through partnerships to tackle difficult and previously untreatable medical targets. Genesis uses its proprietary molecular generation engine, PotentialNet, to generate drug molecules and predict molecular properties. The company has also developed Genesis Exploration of Molecular Spaces (GEMS), a molecular AI platform that combines deep learning, molecular simulations, and language models for molecular generation to develop small molecules for therapies.
 
 
 Key customers and partnerships
 
 
 
 
 In October 2020, Genesis collaborated with 
 <a href="https://www.businesswire.com/news/home/20201019005182/en/Genesis-Therapeutics-Enters-AI-driven-Multi-Target-Drug-Discovery-Partnership-with-Genentech">
 Genentech
 </a>
 to discover and develop novel therapeutics across a variety of therapeutic areas. It also secured a USD 670 million collaboration with 
 <a href="https://sp-edge.com/updates/10108">
 Eli Lilly
 </a>
 in May 2022 to leverage the talent and drug discovery expertise of both parties.
 
 
 
 
 
 Funding and financials
 
 
 
 
 In a 
 <a href="https://sp-edge.com/updates/21189">
 Series B 
 </a>
 funding round in 
 August 2023, co-led by an undisclosed US-based life sciences-focused investor and Andreessen Horowitz Bio + Health, Genesis raised USD 200 million to develop its AI platform and expand its pipeline with new programs.&nbsp;
 
</div>

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response.

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Includes companies that use GenAI as a core part of their product offering for drug discovery & development

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

<div>
 Genesis Therapeutics, a company that uses artificial intelligence for drug discovery, has made key appointments. Shifeng Pan is their new chief scientific officer, Alla Ivanova has been appointed senior vice president of engineering, and Paul A. Friedman is now the chairman of the board.
 These appointments are part of the company's strategy to progress its GEMS AI platform, expand their drug development pipeline, and create innovative treatments for severe diseases. The trio joined the company in 2024.
 Pan has spent more than two decades at Novartis, leading various drug discovery programs. Ivanova possesses 25 years of software development experience, having previously worked at Google Cloud, Atlassian, and Uber. Friedman is seasoned in pharmaceutical research and development, having served as CEO of Madrigal Pharmaceuticals and Incyte.
</div>

Genesis Therapeutics

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless